Associate Professor Dr. Chen Yeng is an expert in cancer biomarker discovery, biosensor development, and natural therapeutics, with a multidisciplinary approach that bridges nanotechnology, molecular biology, and biomedicine. Her expertise is particularly evident in her work on innovative diagnostic technologies and personalized therapeutic solutions, targeting both cancer and infectious diseases.  Her research interests span several cutting-edge areas. One of her primary focuses is the identification and characterization of cancer biomarkers, particularly through novel approaches targeting at immunogenic host proteins. This line of research explores how immunogenic proteins’ interventions might modulate cancer risk, representing an innovative intersection of microbiology, proteomics, and oncology.  Dr. Chen is also deeply engaged in developing advanced diagnostic tools, including nanobiosensors with enhanced sensitivity and specificity. These devices, designed to detect critical biomarkers such as those associated with tuberculosis, blood clotting disorders, and oral cancer, are transformative for early disease detection. Her work in biosensors, utilizing materials like gold nanoparticles and zinc oxide nanolayers, has set new standards in diagnostic accuracy and reliability.  Another cornerstone of her research is the study of natural plant extracts for therapeutic applications, particularly in cancer treatment. She investigates the biochemical and pharmacological properties of these extracts, focusing on their mechanisms of action, such as inducing apoptosis, causing cell cycle arrest, and promoting mitochondrial dysfunction in cancer cells. Her exploration of natural products' roles in modulating microRNAs further highlights her innovative approach to cancer research.  Dr. Chen’s expertise also extends to the antioxidant, hepatoprotective, and genoprotective properties of herbal compounds, offering potential preventive and therapeutic solutions for chronic diseases. These studies underline her commitment to sustainable and natural approaches in healthcare.  Her contributions to genomics and proteomics, particularly in large-scale screening for biological markers, further demonstrate her role as a leader in translating complex biological data into meaningful clinical applications. By combining her deep understanding of molecular biology with a focus on real-world impact, Dr. Chen has established herself as a pioneer in her field.  Dr. Chen’s academic influence is demonstrated by her impressive h-index of 28 (ResearchID) and 39 (Scopus), with over 4,500 citations to her name. Her extensive publication record spans high-impact journals, contributing significantly to advancements in dentistry, oncology, and biomedical engineering. She is recognized as a top scientist in Malaysia, ranking among the leading figures in dentistry according to the AD Scientific Index. As a respected peer reviewer for prestigious journals, including Coordination Chemistry Reviews, Periodontal 2000, Biosensors and Bioelectronics, and Cancer Letters, Dr. Chen plays a critical role in maintaining the quality of research within her fields of expertise. Her contributions extend to academic leadership, where she had supervised and graduated over 20 postgraduate students, including 11 PhD candidates, nurturing the next generation of scientific leaders. Her leadership in dental education accreditation has further solidified her impact on academic excellence. She has played pivotal roles in the reaccreditation of dental programs at the University of Malaya and other institutions, ensuring that these programs meet global standards. Through her commitment to interdisciplinary collaboration, Dr. Chen has partnered with industry leaders to translate research findings into practical healthcare solutions, such as rapid diagnostic tools and personalized treatments. These collaborations exemplify her ability to bridge scientific discovery with real-world applications. In summary, Dr. Chen’s expertise and research interests reflect a holistic approach to biomedical science, integrating cutting-edge technologies with sustainable practices. Her work not only pushes the boundaries of knowledge in cancer research and diagnostics but also has the potential to transform patient care and public health globally.

Noor Asyikeen Mohd Salleh, LL.B. (Hons.) IIUM, Master in Intellectual Property (UKM), has joined the Faculty of Law of University of Malaya as a Lecturer. Prior to joining academia, she was in practice as a conveyancing lawyer at Messrs Iza Ng Yeoh & Kit for 7 years. Her area of interests are conveyancing practice, land acquisition, intellectual property and land law. Being a passionate researcher and academic, she has published in peer-reviewed journals and presented papers in conferences. She also had received a Faculty Research Grant of RM5,000.00 on 11th August 2020 to fund the study on “Land Acquisition in Peninsular Malaysia: Empirical Study On Striking the Right Balance Between Public and Private Interests.

Professor Dr. Lim Kheng Seang, a University of Malaya (Malaysia) graduate in 1999 with MRCP (UK), is a Professor of Neurology in the Faculty of Medicine, University of Malaya, the Head of Neurology Unit, PPUM, and a Consultant Neurologist specializing in epilepsy at the University of Malaya Medical Centre and University Malaya Specialist Centre, Malaysia. He has been trained at the University of Malaya for his neurology subspecialty training (2008), followed by fellowship training in Melbourne (2011) and Cleveland (2017) for epilepsy.  He is the President of the ASEAN Neurological Association (ASNA, 2023-2027), the Chair-elect (2025-2029) and General Secretary (2021-2025) of the Asian and Oceanian Commission, International League Against Epilepsy (ILAE-AO), the chair of the Research Task Force in the commission, the past President of the Malaysian Society of Neurosciences (MSN) and Malaysian Epilepsy Society (PEM), an active member of the Malaysian Epilepsy Council and internationally and ex-chair of the Research Commission in the International Bureau of Epilepsy. He has been involved in many trials of newer treatments (e.g., newer drugs and transcranial magnetic stimulation) in epilepsy. He also specialises in non-invasive and invasive epilepsy surgery assessment, including long-term video-EEG monitoring, intracranial monitoring with stereo-EEG, subdural and depth electrodes, electrocardiography, and cortical stimulation. Other areas of expertise included vagal nerve stimulation, deep brain stimulation, transcutaneous vagal nerve stimulation, repetitive transcranial magnetic stimulation, transcutaneous direct current stimulation, corpus callosotomy and radiofrequency ablation.  He is currently the Associate Editor for Neurology Asia, a reviewer for a few academic journals, and an organising committee member of multiple national and international conferences. He has published ≥ 150 original papers with an H-index of 24, in journals including Neurology (IF:8.055), Epilepsia (IF:5.562), Neuron (14.403), and JAMA Neurology (IF:29.91). His research work focuses on the psychosocial aspects of epilepsy, clinical studies, especially epilepsy surgery and seizures in brain tumours, genetics in focal and familial epilepsies, pharmacogenomics and pharmacokinetics of antiepileptic drugs, quantitative EEG and quantitative MRI research, and artificial intelligence. He is active in research, being the principal investigator and co-investigator in many local and international research projects, and has a strong collaboration with Southeast Asia, Taiwan, Hong Kong, Australia, New Zealand, and the United Kingdom. He was awarded multiple university and national research grants of more than RM1.5 million, and he has supervised 20 postgraduate students and 30 international neurology fellows.